BioAtla, Inc. (NASDAQ:BCAB) Short Interest Down 13.4% in January

BioAtla, Inc. (NASDAQ:BCAB) saw a significant decrease in short interest in January. As of January 31st, there was short interest totalling 4,380,000 shares, a decrease of 13.4% from the January 15th total of 5,060,000 shares. Based on an average daily volume of 1,110,000 shares, the short-interest ratio is currently 3.9 days.

Analyst Ratings Changes

Separately, HC Wainwright lowered shares of BioAtla from a “buy” rating to a “neutral” rating in a research report on Wednesday, November 13th.

Hedge Funds Weigh In On BioAtla

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Boxer Capital Management LLC bought a new position in BioAtla in the fourth quarter valued at approximately $406,000. Jane Street Group LLC boosted its stake in BioAtla by 204.1% in the fourth quarter. Jane Street Group LLC now owns 149,291 shares of the company’s stock valued at $88,000 after acquiring an additional 100,204 shares during the last quarter. Renaissance Technologies LLC boosted its stake in BioAtla by 62.2% in the fourth quarter. Renaissance Technologies LLC now owns 829,596 shares of the company’s stock valued at $490,000 after acquiring an additional 318,196 shares during the last quarter. Highbridge Capital Management LLC bought a new position in BioAtla in the fourth quarter valued at approximately $1,484,000. Finally, Norges Bank bought a new position in BioAtla in the fourth quarter valued at approximately $230,000. 77.23% of the stock is owned by institutional investors.

BioAtla Price Performance

BCAB stock traded up $0.03 during midday trading on Friday, reaching $0.46. The company’s stock had a trading volume of 1,711,107 shares, compared to its average volume of 665,159. BioAtla has a 52 week low of $0.38 and a 52 week high of $4.02. The business’s 50-day simple moving average is $0.68 and its 200-day simple moving average is $1.41.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.